ArticleMolecular medicine reports2018
miR‑539 suppresses proliferation and induces apoptosis in renal cell carcinoma by targeting high mobility group A2.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- An engineered tumor organoid model reveals cellular identity and signaling trajectories underlying SFPQ-TFE3 driven translocation RCC.iScience · 2025Article
- Deregulated expression of the 14q32 miRNA cluster in clear cell renal cancer cells.Frontiers in oncology · 2023Article
- High Mobility Group A (HMGA): Chromatin Nodes Controlled by a Knotty miRNA Network.International journal of molecular sciences · 2020Review
- miR-539-3P inhibits proliferation and invasion of gastric cancer cells by targeting CTBP1.International journal of clinical and experimental pathology · 2019Article
- MicroRNA-539 inhibits the progression of Wilms' Tumor through downregulation of JAG1 and Notch1/3.Cancer biomarkers : section A of Disease markers · 2019Article
- Down-regulation of MiR-539 Indicates Poor Prognosis in Patients with Pancreatic Cancer.Open life sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is one of the most common urinary malignancies with a high rate of morbidity. MicroRNAs (miRNAs) have been shown to be critical post‑transcriptional regulators in tumorigenesis. The present study aimed to investigate the effect of miRNA (miR)‑539 on the proliferation and apoptosis of RCC. The expression of miR‑539 and high mobility group AT‑hook 2(HMGA2) were examined in clinical RCC specimens. The 786‑O RCC cell line was also used and was transfected with miR‑539 mimics or inhibitors. The correlation between miR‑539 and HMGA2 was confirmed using a luciferase reporter assay. Cell viability and apoptosis were detected using MTT and flow cytometry assays. The protein levels of HMGA2, AKT, phosphorylated (p)‑AKT, mammalian target of rapamycin (mTOR) and p‑mTOR were analyzed using western blot analysis. The results revealed that miR‑539 was negatively correlated with the expression of HMGA2 in clinical RCC specimens. Further experiments identified HMGA2 as a direct target of miR‑539. The overexpression of miR‑539 downregulated the expression of HMGA2, reduced cell proliferation and promoted cell apoptosis, whereas the knockdown of miR‑539 led to the opposite results. miR‑539 also suppressed the phosphorylation of AKT and mTOR, without altering the levels of total AKT and mTOR. Taken together, the results of the present study indicated that miR‑539 negatively regulated the expression of HMGA2 in clinical specimens and in vitro. miR539 inhibited cell proliferation and induced apoptosis in RCC cells. This regulatory effect of miR‑539 may be associated with the AKT signaling pathway. Therefore, miR‑539 may be used as a biomarker for predicting the progression of RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.